Deutsche Bank Aktiengesellschaft Upgrades Gilead Sciences (NASDAQ:GILD) to "Buy"

Gilead Sciences (NASDAQ:GILD - Get Free Report) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating in a note issued to investors on Tuesday, MarketBeat reports. The brokerage presently has a $120.00 target price on the biopharmaceutical company's stock, up from their previous target price of $80.00. Deutsche Bank Aktiengesellschaft's price objective points to a potential upside of 9.14% from the company's current price.

A number of other analysts also recently issued reports on the company. Royal Bank of Canada raised their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Barclays boosted their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Thursday, November 7th. Wells Fargo & Company lifted their price target on Gilead Sciences from $105.00 to $120.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Leerink Partners raised Gilead Sciences from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Finally, Truist Financial boosted their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research note on Friday, November 8th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $102.08.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $0.08 during mid-day trading on Tuesday, reaching $109.95. 9,729,048 shares of the company's stock were exchanged, compared to its average volume of 7,379,648. The business's fifty day simple moving average is $95.41 and its 200 day simple moving average is $88.63. The firm has a market capitalization of $137.03 billion, a PE ratio of 297.16, a P/E/G ratio of 0.71 and a beta of 0.18. Gilead Sciences has a one year low of $62.07 and a one year high of $111.03. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, sell-side analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the firm's stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 713,000 shares of company stock valued at $67,945,181. 0.16% of the stock is owned by company insiders.

Institutional Trading of Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in Gilead Sciences in the third quarter worth about $25,000. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $28,000. Finally, Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $29,000. Institutional investors own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.